Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)
Funding opportunity to support HIV/AIDS research tackling hearing, balance, taste, smell, voice, speech, & language within NIDCD's mission.
Funder: National Institutes of Health
Due Dates: May 7, 2025 | September 7, 2025 | January 7, 2026 | May 7, 2026 | July 5, 2026
Funding Amounts: Up to $499,999 direct costs per year, for up to 5 years (R01 mechanism).
Summary: Supports research on HIV/AIDS within the NIDCD mission areas (hearing, balance, taste, smell, voice, speech, language), including low-risk clinical trials.
Key Information: Only low-risk clinical trials are allowed; standard NIH AIDS due dates apply.
Description
This funding opportunity supports research that advances understanding of HIV/AIDS as it relates to the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD). The focus is on high-priority HIV/AIDS research, as outlined by the NIH Office of AIDS Research (OAR), in the domains of hearing, balance, taste, smell, voice, speech, and language. The program encourages hypothesis-driven epidemiological, basic, translational, and clinical research, including multidisciplinary collaborations and leveraging of existing HIV/AIDS cohorts or clinical trials.
For applications proposing clinical trials, only those classified as "low risk"—not requiring FDA IND/IDE oversight, with minimal risk, and not designed to establish efficacy or change standard of care—will be considered. Projects outside these parameters should consider other NIDCD funding mechanisms.
